Positive outcome for Lofarma papers
regarding the Allergy Specific Immunotherapy in tablets called L.A.I.S.
AIFA (the Italian Medicine Agency) conveyed that the process to release the Marketing Authorisation is allowed to continue for the Allergy Specific Immunotherapy in tablets (all allergens), the subcutaneous therapy LAIS-In, the subcutaneous depot and the skin prick tests!
So both the registration process and the availability of our products continue without any interruption.
This means that the commitment of Lofarma to pursue its innovation and research mission also continues, so to provide efficient and well tolerated allergy pharmaceutical products, contributing to the growth of the so called «Made in Italy»!